@article{RECOVERY_Collaborative_Group-2022_90823,
title = {Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial},
author = {RECOVERY Collaborative Group},
month = {feb},
year = {2022},
abstract = {Casirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike glycoprotein, blocking viral entry into host cells. We aimed to evaluate the efficacy and safety of casirivimab and imdevimab administered in combination in patients admitted to hospital with COVID-19.},
pages = {665-676},
volume = {399},
issue = {10325},
journal = {The Lancet},
publisher = {Elsevier},
url = {https://doi.org/10.1016/S0140-6736(22)00163-5},
}
